JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 3 October 2005. doi:10.1083/jcb1711rr3
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 171, Number 1, 11-11
This Article
Right arrow Full Text (PDF, 471K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Roundup

Antiviral walls


The innate immune system has the tricky task of foiling all invaders rather than targeting a specific few. Eugenia Leikina, Leonid Chernomordik (NICHHD, Bethesda, MD), and colleagues report that defensin antimicrobial peptides use a unique nonspecific method: they cross-link surface glycoproteins and thus freeze them in place. The resulting web of proteins obstructs the fusion of viral and cell membranes.

Defensins caught Chernomordik's eye because he works on membrane fusion and the defensins have broad specificity. He thought they might interfere with membrane properties, but was disappointed when they accelerated rather than inhibited fusion between protein-free liposomes.

With virus-infected cells, however, things got more interesting. Defensins did not block virus binding or endocytic uptake but did block membrane fusion. Membrane glycoproteins no longer diffused over the membrane surface.

The lack of diffusion may be the key. When a virus binds to a cell there is still a gap of ~10 nm between the membranes, which can be closed only when proteins in a tiny patch happen, via random diffusion, to get out of the way. With defensins bound, suggests Chernomordik, "the proteins would not move away."

"This might be the first natural antiviral agent targeting fusion," says Chernomordik. "The fusion stage targeted is elusive, because if proteins are mobile it is not rate limiting." He also notes a tantalizing analogy to prokaryotes, which use covalently cross-linked proteoglycans as a barrier, forcing bacteriophages to use injection rather than fusion mechanisms. "For a short time," he says, "our cells become prokaryotic by erecting these walls." {rr_end}

Reference:

Leikina, E., et al. 2005. Nat. Immunol. doi:10.1038/ni1248.



William A. Wells

wellsw{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 471K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents